Drug Trial Radar · NCT00158600
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
Last checked: Nov 20, 2026Latest source record: Apr 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Sep 2005
Primary completion
Sep 2007
Study completion Sep 2007
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of alglucosidase alfa treatment in patients with late-onset Pompe disease as compared to placebo.
Conditions
- Pompe Disease (Late-onset)
- Glycogen Storage Disease Type II (GSD-II)
- Acid Maltase Deficiency Disease
- Glycogenosis 2
Interventions
alglucosidase alfaBiological
IV infusion of 20mg/kg; qow for 78 weeks.
PlaceboDrug
Placebo Comparator; qow for 78 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of Patients Reporting Treatment-Emergent Adverse EventsTime frame: weeks 0-78
- Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From BaselineTime frame: weeks 0, 78
- Percent of Predicted Forced Vital Capacity (FVC)Time frame: weeks 0, 78
- Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)Time frame: weeks 0, 12 and 52
- Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax)Time frame: weeks 0, 12, 52
- Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax)Time frame: weeks 0, 12, 52
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Tower Hematology Oncology Medical Group
Beverly Hills, California
Children's National Medical Center
Washington D.C., District of Columbia
Washington University Medical Center
St Louis, Missouri
Mount Sinai School of Medicine
New York, New York
University of Pittsburgh, Dept. of Neurology
Pittsburgh, Pennsylvania
Groupe Hospitalier Pitie-Salpetriere
Paris, France
Sophia Children's Hospital, Erasmus MC
Rotterdam, Netherlands
Erasmus Medical Centre Rotterdam
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.